INDP indaptusrx.com: Company Value to Revenue Ratio

Indaptus Therapeutics (INDP) operates as a pre-revenue startup, consuming capital for research. Its R&D specifics rely on external bacterial synthesizers and contract manufacturing of tumor-fighting drugs. The EV/Sales history on the GURU.Markets terminal linear chart confirms the absence of revenue, while 0.00 is recorded as the baseline value, reflecting the valuation's dependence on third-party vendor charts.
Financial and market metric breakdowns for Indaptus Therapeutics, Inc. (INDP)

This indicator measures the enterprise value of the business, accounting for net debt per unit of revenue, allowing for an assessment of investor overpayment for current sales without distortions from financial leverage. When analyzing the EV/Revenue ratio, one should look for undervaluation relative to the sector, which for Indaptus Therapeutics (INDP) is supported by the high value of a stable staff of research biochemists who ensure the long-term potential for immunotherapy development.